TRACE PDX platform

A discouraging high failure rate characterizes oncology trials. This is partly due to the use of inappropriate preclinical models. Patient-derived xenograft (PDX) models, where fragments of patient's tumours are transplanted into mice, faithfully recapitulate the human intra-tumour and intra-patient heterogeneity and thus reliably predict therapy responses. At Trace, we establish & characterize PDXs of different tumour types and offer this unique in vivo collection for all levels of cancer drug discovery. Our models are annotated with molecular and clinical data thus allowing to correlate therapeutic response with specific molecular features for a personalized medicine approach.

Our team specializes in the development and characterization of patient-derived xenograft (PDX) models, enabling highly translational in vivo studies. We conduct comprehensive drug efficacy and toxicity assessments, supported by in vivo imaging capabilities for real-time monitoring of tumor progression and treatment response. We have extensive expertise with orthotopic PDX models and humanized mouse systems, allowing the study of tumor–microenvironment interactions and immuno-oncology therapies in clinically relevant settings. We also provide ex vivo analyses to complement in vivo findings, delivering a complete preclinical workflow from model generation to mechanistic insight.